Back to Peptides
CJC-1295 with DAC
Growth Factors & Muscle BuildingCJC-1295 with DAC (Drug Affinity Complex) is a long-acting growth hormone-releasing hormone (GHRH) analog. The DAC modification extends its half-life to 6–8 days by binding to serum albumin, enabling once or twice-weekly dosing instead of the multiple daily injections required by the no-DAC version (Mod GRF 1-29). It produces sustained, non-pulsatile GH elevation.
Reconstitute
3 mL BAC + 2mg vial
7 mcg/unit
Daily Range
300–1000 mcg Subcutaneous (SQ)
1-2 times per week
Standard Dose
600 mcg
Cycle
4–8 weeks
then reassess
growth hormoneGHRH analogDACDrug Affinity ComplexIGF-1anti-agingbody compositionlong-acting
Dosing & Reconstitution Guide
CJC-1295 with DAC produces sustained, non-pulsatile GH elevation — unlike the no-DAC version which mimics natural GH pulses. This may increase side effects including water retention, insulin resistance, and receptor downregulation. Do not stack with other long-acting GH secretagogues. Monitor IGF-1, glucose, and insulin levels.
Standard / Gradual Approach
2mg VialstandardPhaseDoseVolume
Week 11mg150 units
Week 61mg150 units
Week 111.5mg225 units
Week 162mg300 units
Protocol Summary
Subcutaneous (SQ): 1-2 times per week · Dose range 300–1000 mcg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending
Frequency & Cycling
Subcutaneous (SQ)
Inject 1–2x weekly, spaced 3–4 days apart. Cycle: 8–12 weeks on, 4 weeks off to preserve receptor sensitivity. Some protocols use continuous dosing under medical supervision.
🧪 Quick Start
Vial Size
2 mg
BAC Water
3 mL
Concentration
700 mcg/unit
Potential Benefits & Use Cases
CJC-1295 with DAC is an investigational peptide not approved by the FDA for therapeutic use. All dosing information is based on published research and clinical trials. Consult a qualified healthcare provider before use.
Supports sustained GH and IGF-1 elevation for 6–11 days per injection (human trial data)
May enhance lean body mass and reduce visceral adiposity (Phase 2 data)
Supports improved recovery from exercise and tissue repair
Convenient dosing schedule (1–2x weekly vs. daily for no-DAC version)
May support collagen synthesis and joint health
Supports improved sleep quality through sustained GH elevation
Clinical data Strong preclinical Limited data
Mechanism of Action
→Binds to GHRH receptors on anterior pituitary somatotroph cells, stimulating growth hormone synthesis and secretion
→Drug Affinity Complex (DAC) covalently bonds to circulating albumin, extending plasma half-life from minutes to 6–8 days
→Produces sustained, elevated GH and IGF-1 levels rather than natural pulsatile release
Stacking Synergies
+
Ipamorelin
Often combined with Ipamorelin for enhanced GH release
+
GHRP-2
Can be stacked with GHRP-2 for synergistic GH effect (caution with sustained levels)
+
GHRP-6
Can be stacked with GHRP-6 for synergistic GH effect (caution with sustained levels)
+
Semaglutide
Pairs well with Semaglutide or Tirzepatide for body composition goals
Lifestyle & Optimization
diet
Caloric surplus (300–500 above maintenance). 1–1.2g protein per pound body weight.
sleep
Prioritize 8–10 hours of sleep nightly for maximum GH secretion.
timing
Inject 1–2x weekly, spaced 3–4 days apart. Evening dosing preferred.
exercise
Heavy resistance training 4–5 times weekly.
Peptide Research & Preclinical Studies
Evidence-Based Research Findings
Side Effects & Safety
Common Side Effects
• Injection site reactions (redness, swelling, itching)
• Transient flushing or 'head rush' after injection
• Water retention and mild peripheral edema
• Headache (more common than with no-DAC version due to sustained GH elevation)
Contraindications & Warnings
• May cause sustained GH elevation that does not mimic natural pulsatile release — higher side effect risk vs. no-DAC
• Potential for GH receptor downregulation with prolonged continuous use
• Do not use in patients with active malignancy or pituitary tumors
• Monitor blood glucose — sustained GH elevation may reduce insulin sensitivity
Long-Term Safety Data
• Possible carpal tunnel symptoms with chronic use
• Potential temporary suppression of natural GH rhythm
• Risk of insulin resistance with extended high-dose protocols
🧮 Dose Calculator
Concentration
6.7
mcg/unit
Draw Volume
75
units (0.750 mL)
For a 500 mcg dose, draw 75 units on a U-100 insulin syringe
🧬
Bioavailability & Absorption
SubQ Injection
High subcutaneous bioavailability; DAC modification extends plasma half-life from minutes to 6–8 days via albumin binding
Oral Administration
Not available orally due to peptide degradation in the GI tract
Half-Life
6–8 days (vs ~30 minutes for no-DAC version)
Degradation
Slowly cleared due to albumin binding; DAC protects from enzymatic degradation
Tissue Specificity
Targets anterior pituitary somatotroph cells via GHRH receptors
⚗️
Peptide Details
Molecular Weight
3647.28
Formula
Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(DAC)-NH2
⚖️
Legal Status & Regulatory
RegionStatus
EUNot Approved
FDANot Approved
CanadaNot Approved
AustraliaNot Approved
Storage Instructions
Lyophilized (Powder)
Store lyophilized powder at 2-8°C
Reconstituted (Mixed)
After reconstitution, maintain at 2-8°C and use within 30 days. The DAC formulation is more stable than standard CJC-1295.